Acute Cardiac Ischemia

MPC-25-IC is Mesoblast’s Phase 2 product candidate for the treatment of acute myocardial infarction. This is the first clinical study to evaluate an allogeneic cellular therapy delivered by intracoronary infusion in patients who have suffered an acute myocardial infarction.

Disease Indication and Patient Population

The majority of heart attack patients undergo angioplasty and stent procedures successfully. However, despite maximal therapy a subset of these patients remain at high risk of progressing to develop heart failure over the ensuing two years. For these patients a therapy that can protect at-risk heart muscle cells from dying by delivery via intra-coronary administration at the time of the angioplasty may prevent this major complication.


Mesenchymal precursor cells (MPCs) release factors that induce functional cardiac recovery by simultaneous regeneration of the endogenous vascular network formation as well as endogenous cardiomyocytes or cardiomyocyte precursors, compared to only small vessel angiogenesis obtained with hematopoietic stem cells which only give rise to the endothelium of capillaries.

Mechanism of Action

MPCs release factors that may induce functional cardiac recovery by simultaneously regenerating the endogenous vascular network as well as endogenous cardiomyocytes or cardiomyocyte precursors.

Preclinical studies have shown that, when injected into ischemic myocardium, MPCs are potent inducers of large caliber arteriogenesis. This is in comparison with hematopoietic stem cells which stimulate small vessel angiogenesis and give rise to the endothelium of capillaries.

Clinical Trials

Ongoing Phase 2 Trial

Following a positive sheep intracoronary preclinical study, a Phase 2 allogeneic trial for Acute myoCardial Infarction (AMICI) trial of MPC-25-IC is actively enrolling patients.

The AMICI trial is a prospective, randomized, placebo-controlled, double blind clinical trial that will analyze the effect of intracoronary infusion of MPCs in patients with an ST-elevation myocardial infarction (STEMI) of the anterior wall. The Phase 2b trial is actively recruiting across multiple sites in Europe.

The primary safety endpoint is the occurrence of major adverse cardiac events at 30 days follow up, with the secondary efficacy endpoint defined as reduction in the left ventricular end-systolic volume measured from baseline to six months.

Find out more about this Phase 2 trial